MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Sees Significant Growth in Short Interest

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) saw a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 1,983,177 shares, an increase of 21.5% from the January 15th total of 1,632,436 shares. Approximately 7.9% of the company’s shares are sold short. Based on an average trading volume of 2,033,323 shares, the days-to-cover ratio is currently 1.0 days. Based on an average trading volume of 2,033,323 shares, the days-to-cover ratio is currently 1.0 days. Approximately 7.9% of the company’s shares are sold short.

Insider Buying and Selling

In other news, Director Stan Smith purchased 57,189 shares of the stock in a transaction on Monday, December 22nd. The stock was purchased at an average price of $1.22 per share, for a total transaction of $69,770.58. Following the acquisition, the director owned 1,421,478 shares in the company, valued at $1,734,203.16. This trade represents a 4.19% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ngar Yee Louie purchased 81,699 shares of the company’s stock in a transaction dated Monday, December 22nd. The stock was purchased at an average price of $1.22 per share, for a total transaction of $99,672.78. Following the transaction, the director directly owned 1,248,888 shares in the company, valued at approximately $1,523,643.36. This trade represents a 7.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have acquired 349,122 shares of company stock valued at $402,193. Insiders own 32.32% of the company’s stock.

Hedge Funds Weigh In On MAIA Biotechnology

Hedge funds have recently added to or reduced their stakes in the stock. Centerpoint Advisory Group purchased a new stake in shares of MAIA Biotechnology in the second quarter worth approximately $28,000. Marshall Wace LLP purchased a new stake in MAIA Biotechnology in the 2nd quarter valued at $29,000. Ritholtz Wealth Management bought a new position in MAIA Biotechnology during the 4th quarter valued at $35,000. Jane Street Group LLC purchased a new position in MAIA Biotechnology during the 2nd quarter worth $52,000. Finally, Geode Capital Management LLC grew its stake in shares of MAIA Biotechnology by 3.6% in the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after acquiring an additional 7,746 shares in the last quarter. Institutional investors and hedge funds own 5.65% of the company’s stock.

MAIA Biotechnology Trading Down 2.5%

Shares of MAIA stock opened at $1.92 on Tuesday. The firm has a fifty day simple moving average of $1.77 and a two-hundred day simple moving average of $1.54. MAIA Biotechnology has a 12 month low of $0.87 and a 12 month high of $3.19. The firm has a market capitalization of $71.10 million, a PE ratio of -2.63 and a beta of -0.07.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.